Project Grant R56HL175336
Award Date
9/17/24
Completion Date
8/31/25
Dollars Obligated
$1.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $124,536 to The General Hospital Corporation (Massachusetts General Hospital) to study the protective role of B cells in hyperoxic lung injury. The key objectives are to characterize the dynamics of B cell responses during hyperoxia exposure, examine the protective impacts of B cell supplementation, and investigate mechanistic...
This $704,795 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Baylor College of Medicine supports the development of a novel cell-based immunomodulation therapy to suppress lung inflammation and promote repair in Acute Respiratory Distress Syndrome (ARDS). The project aims to engineer retinal pigment epithelial (RPE) cells to produce anti-inflammatory cytokines IL-1RA and IL-10 and encapsulate them in alginate-based...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,099 to the Massachusetts Institute of Technology (MIT) to conduct research on treatment strategies for Acute Respiratory Distress Syndrome (ARDS). The key products and services to be delivered under this grant include: Utilizing "target trial emulation" and advanced causal inference methods to analyze observational data...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $1,147,992 to The Regents of the University of California, San Francisco (UCSF) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to advance precision medicine for acute respiratory distress syndrome (ARDS) and sepsis by addressing key unanswered questions about the functional immune response, biological pathways, and optimization of real-time phenotyping in these critical care...
This $782,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of TREK-1 potassium channels in acute respiratory distress syndrome (ARDS). The key objectives are to: 1) determine if ARDS decreases epithelial and endothelial TREK-1 levels, leading to cell membrane depolarization and calcium-dependent inflammation, and 2) evaluate if activating residual TREK-1...
This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
This Project Grant award, identified as R01HL170118, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award, totaling $495,159.00, will fund research to investigate the role of the protein CARMIL1 in regulating endothelial cell barrier function and its potential impact on acute respiratory distress syndrome (ARDS). The study, to be conducted by the University of Illinois, will use...
This federal Project Grant award for $775,992 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of regulatory T cells (Tregs) and glucocorticoid signaling in the resolution of acute lung injury and acute respiratory distress syndrome (ARDS). The key objectives are to determine how glucocorticoid signaling in Tregs impacts their immunomodulatory and tissue reparative effects during lung...
The federal Project Grant award R01HL173531, totaling $737,815, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award supports the development and validation of an automated electronic health record (EHR)-embedded Clinical Classifier Model (CCM) system to rapidly identify distinct molecular phenotypes of acute respiratory distress syndrome (ARDS) and sepsis at the bedside. This will enable...